Effects of Cytokine Therapy for Treatment and Prophylaxis of Hydatidosis in Experimental Animal Model (Mice)

  • Mahmoud RAHDAR Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran and Dept. of Parasitology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  • Abdollah RAFIEI Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran and Dept. of Parasitology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  • Rohollah VALIPOUR NOROUZI Dept. of Parasitology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Keywords: Hydatid cyst, Cytokine therapy, Mice

Abstract

Background: We aimed to use of IL-12 and IFN-γ for prevention and treatment of hydatidosis in experimental animal models. Methods: This experimental study was conducted in Ahvaz City, southwest of Iran in 2017.  Forty female BALB/C mice with 6-8 wk old were divided into four groups (two group test and two group control). The mice were challenged with 2000 protoscolices and a combination of IL-12 (10 µg/kg) and IFN-γ (25 µg/kg) was injected intraperitoneally daily one week at the time of challenging (prevention group) and three months after challenging (treatment group). After four months, the mice were euthanized and the number, size, and weight of the cysts were measured in all studied groups. Pathologic slides were prepared from cyst wall for pathologic changes study. Results: There issignificant reduction in number, size, and weight of cysts in test groups. Conclusion: Cytokine therapy is effective methods especially for prevention of cyst formation and to treat non-operable cases. Further study of combination of chemotherapy and cytokine therapy should be investigated.

References

References

Lewall DB. Hydatid disease: Biology, pathology, imaging and classification. Clinical radiology. 1998;53(12):863-74.

Sherlock S. Hydatid disease: Disease of liver and biliary system. Oxford: Blackwell Scientific Publications; 1981.

Anadol D, Ozcelik U, Kiper N, Gocmen A. Treatment of hydatid disease. Paediatric drugs. 2001;3(2):123-35.

Bonifacino R, Dogliani E, Craig PS. Albendazole treatment and serological follow-up in hydatid disease of bone. International orthopaedics. 1997;21(2):127-32.

Henry Knipe H, Gaillard F. Hydatid disease. https://radiopaedia.org/articles/hydatid-disease; [cited]; Available from.

Riganò R, Profumo E, Ioppolo S, Notargiacomo S, Ortona E, Teggi A, et al. Immunological markers indicating the effectiveness of pharmacological treatment in human hydatid disease. Clinical and Experimental Immunology. 1995;102(2):281-5.

Rigano R, Profumo E, Ioppolo S, Notargiacomo S, Teggi A, Siracusano A. Serum cytokine detection in the clinical follow up of patients with cystic echinococcosis. Clin Exp Immunol. 1999;115(3):503-7.

Rahdar M, Rafiei A, Jamshidian M, Hashemitabar M, Ghaforian M, Rasekh A. In vitro Production of IL4, IL5 and IL10 in Peripheral Blood mononuclear cell Culture from Human Hydatidosis. Biochem Cell Arch. 2005;5:29-36.

Germann T, Gately MK, Schoenhaut DS, Lohoff M, Mattner F, Fischer S, et al. Interleukin-12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells. European journal of immunology. 1993;23(8):1762-70.

Kang K, Kubin M, Cooper KD, Lessin SR, Trinchieri G, Rook AH. IL-12 synthesis by human Langerhans cells. Journal of immunology. 1996;156(4):1402-7.

D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste M, et al. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. The Journal of experimental medicine. 1992;176(5):1387-98.

Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. The Journal of experimental medicine. 1989;170(3):827-45.

Wolf SF, Temple PA, Kobayashi M, Young D, Dicig M, Lowe L, et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. Journal of immunology. 1991;146(9):3074-81.

Gray PW, Goeddel DV. Structure of the human immune interferon gene. Nature. [10.1038/298859a0]. 1982;298(5877):859-63.

Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Advances in immunology. 2007;96:41-101.

Amri M, Touil-Boukoffa C. In vitro anti-hydatic and immunomodulatory effects of ginger and [6]-gingerol. Asian Pacific Journal of Tropical Medicine. 2016;9(8):749-56.

Labsi M, Khelifi L, Mezioug D, Soufli I, Touil-Boukoffa C. Antihydatic and immunomodulatory effects of Punica granatum peel aqueous extract in a murine model of echinococcosis. Asian Pacific Journal of Tropical Medicine. 2016;9(3):211-20.

Rivero-Lezcano OM. Cytokines as immunomodulators in tuberculosis therapy. Recent patents on anti-infective drug discovery. 2008;3(3):168-76.

Atretkhany KN, Drutskaya MS. Myeloid-Derived Suppressor Cells and Proinflammatory Cytokines as Targets for Cancer Therapy. Biochemistry Biokhimiia. 2016;81(11):1274-83.

Zhang L, Hao CQ, Miao L, Dou XG. Role of Th1/Th2 cytokines in serum on the pathogenesis of chronic hepatitis C and the outcome of interferon therapy. Genetics and molecular research : GMR. 2014;13(4):9747-55.

Romagnani S. The Th1/Th2 paradigm. Immunology today. 1997;18(6):263-6.

Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996;383(6603):787-93.

Ghosh K, Sharma G, Saha A, Kar S, Das PK, Ukil A. Successful therapy of visceral leishmaniasis with curdlan involves T-helper 17 cytokines. The Journal of infectious diseases. 2013;207(6):1016-25.

de Assis Souza M, de Castro MC, de Oliveira AP, de Almeida AF, de Almeida TM, Reis LC, et al. Cytokines and NO in American tegumentary leishmaniasis patients: profiles in active disease, after therapy and in self-healed individuals. Microbial pathogenesis. 2013;57:27-32.

Desai D, Brightling C. Cytokines and cytokine-specific therapy in asthma. Advances in clinical chemistry. 2012;57:57-97.

Khamaganova IV, Akhmedov Kh B, Tarabrina NP, Khromova SS, Mezentseva MV, Koval'chuk LV, et al. [Effect of combined therapy using complex of natural cytokines and antimicrobial peptides in urogenital infections caused by Chlamydia and Mycoplasma]. Zhurnal mikrobiologii, epidemiologii, i immunobiologii. 2011(1):90-3.

Mullen L, Adams G, Layward L, Vessillier S, Annenkov A, Mittal G, et al. Latent cytokines for targeted therapy of inflammatory disorders. Expert opinion on drug delivery. 2014;11(1):101-10.

Kilwinski J, Jenne L, Jellen-Ritter A, Radloff P, Flick W, Kern P. T lymphocyte cytokine profile at a single cell level in alveolar Echinococcosis. Cytokine. 1999;11(5):373-81.

Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK. Recombinant interleukin 12 cures mice infected with Leishmania major. The Journal of experimental medicine. 1993;177(5):1505-9.

Sedegah M, Finkelman F, Hoffman SL. Interleukin 12 induction of interferon gamma-dependent protection against malaria. Proceedings of the National Academy of Sciences of the United States of America. 1994;91(22):10700-2.

Hunter CA, Slifer T, Araujo F. Interleukin-12-mediated resistance to Trypanosoma cruzi is dependent on tumor necrosis factor alpha and gamma interferon. Infection and immunity. 1996;64(7):2381-6.

Wynn TA, Eltoum I, Oswald IP, Cheever AW, Sher A. Endogenous interleukin 12 (IL-12) regulates granuloma formation induced by eggs of Schistosoma mansoni and exogenous IL-12 both inhibits and prophylactically immunizes against egg pathology. The Journal of experimental medicine. 1994;179(5):1551-61.

Amiot F, Vuong P, Defontaines M, Pater C, Dautry F, Liance M. Secondary alveolar echinococcosis in lymphotoxin-alpha and tumour necrosis factor-alpha deficient mice: exacerbation of Echinococcus multilocularis larval growth is associated with cellular changes in the periparasitic granuloma. Parasite immunology. 1999;21(9):475-83.

Emery I, Liance M, Deriaud E, Vuitton DA, Houin R, Leclerc C. Characterization of T-cell immune responses of Echinococcus multilocularis-infected C57BL/6J mice. Parasite immunology. 1996;18(9):463-72.

Liance M, Ricard-Blum S, Emery I, Houin R, Vuitton DA. Echinococcus multilocularis infection in mice: in vivo treatment with a low dose of IFN-gamma decreases metacestode growth and liver fibrogenesis. Parasite (Paris, France). 1998;5(3):231-7.

Emery I, Leclerc C, Sengphommachanh K, Vuitton DA, Liance M. In vivo treatment with recombinant IL-12 protects C57BL/6J mice against secondary alveolar echinococcosis. Parasite immunology. 1998;20(2):81-91.

Published
2018-12-19
How to Cite
1.
RAHDAR M, RAFIEI A, VALIPOUR NOROUZI R. Effects of Cytokine Therapy for Treatment and Prophylaxis of Hydatidosis in Experimental Animal Model (Mice). Iran J Parasitol. 13(4):587-593.
Section
Original Article(s)